Integration-Deficient Lentiviral Vector (IDLV) Packaging

1. Service Overview

Integration-Deficient Lentivirus (IDLV) is a precision-engineered lentiviral vector system. Through targeted mutation of the critical catalytic residue of the integrase (D64V), the DDE catalytic triad of the integrase is disrupted, permanently abolishing the virus’s ability to integrate its genome into host chromosomes following reverse transcription, while fully preserving the core advantage of efficient transduction of both dividing and non-dividing cells. After transduction, the viral genome persists stably within the nucleus as episomal circular DNA (episomal cDNA), enabling transient yet highly efficient expression of the transgene. The episome is gradually diluted and eliminated as cells proliferate and divide, fundamentally eliminating the safety risk of insertional mutagenesis. The integration rate can be reduced to below 0.01% of that of standard lentiviral vectors.

The therapeutic and immunological potential of IDLV has been substantiated across multiple disease areas in peer-reviewed studies:

In the field of HIV therapeutic vaccines, non-human primate (NHP) studies demonstrated that following a single injection of an IDLV vaccine expressing SIV-Gag, more than half of the subjects achieved sustained viremia control lasting over 20 weeks — representing the first animal model validation of IDLV for the therapeutic control of chronic HIV infection¹. Further research showed that IDLV episomes persisted in the muscle at the injection site for up to 6 months in non-human primates, continuously driving immune responses as an antigen reservoir, suggesting the feasibility of durable protection through a single immunization².

In the field of HIV prophylactic vaccines, a single injection of IDLV carrying native-conformation HIV-1 Env trimers elicited antibody responses with a significantly longer half-life than conventional protein vaccines. Following booster immunization, neutralizing activity against autologous virus was observed in some animals, supporting further clinical development of IDLV as a platform for broadly neutralizing antibody induction³.

In the field of gene-editing therapy, a recent study developed a dual-component IDLV system carrying GALNS cDNA and Cas9/sgRNA for gene knock-in treatment of mucopolysaccharidosis (MPS). Following injection into neonatal mice, sustained restoration of enzyme activity and partial correction of pathological features were observed, with no significant toxicity or immune reaction throughout the study, validating the safety and feasibility of the IDLV-CRISPR combined platform for treating rare genetic diseases⁴.

To date, IDLV has accumulated robust preclinical evidence across five major clinical application areas: gene therapy, cell reprogramming, gene editing, targeted cell elimination, and vaccine immunization. It is currently advancing rapidly toward early-phase clinical translation.

We offer a comprehensive, one-stop IDLV packaging service — from vector design to viral production — providing safe and highly efficient solutions for your research and clinical translation needs.

Fig1. Schematic diagram of IDLV structure and selected applications

2. Core Technical Advantages

2.1 Significantly Enhanced Safety

• Zero insertional mutagenesis risk: No integration into the host genome, eliminating the risk of proto-oncogene activation or tumor suppressor gene disruption

• Non-genotoxic: Suitable for preclinical research and cell therapy applications

• Controllable expression duration: Gradual dilution with cell division leads to natural expression attenuation

• Regulatory compliance: Meets FDA/EMA safety standards for gene therapy products

2.2 High Transduction Efficiency

• Broad host range: Capable of transducing both dividing and non-dividing cells (neurons, hepatocytes, hematopoietic stem cells, etc.)

• High transduction efficiency: Comparable to integrating lentivirus (60–90%)

• Rapid onset: Transgene expression detectable within 24–48 hours post-transduction

• Strong dose-dependence: Enables precise control of expression levels

2.3 Versatile Application Flexibility

• Transient expression studies: Gene function validation, signaling pathway research

• Reprogramming applications: iPSC induction (Oct4/Sox2/Klf4/c-Myc) without integration risk

• Vaccine vector: Antigen presentation research, immunogenicity assessment

• CRISPR tool delivery: Transient Cas9/sgRNA expression to reduce off-target effects

• CAR-T cell preparation: Transient CAR molecule expression for functional screening

2.4 Proven and Reliable Technology

• D64V mutant system: Integration rate <0.1%

• High-titer guarantee: Standard titer ≥1×10⁸ TU/mL

• Batch-to-batch consistency: Stringent manufacturing process control; inter-batch variation <15%

• Comprehensive QC: Full testing for titer, purity, sterility, endotoxin, and integration rate

Fig2. Schematic diagram of IDLV technical advantages

3. Service Offerings

We currently provide Integration Deficient Lentiviral vectors in a variety of specifications for in vitro and in vivo experiments, meeting the diverse research needs of our clients. Specific service offerings are detailed below:

3.1 Standard IDLV Packaging Service

• Vector construction and sequence verification

• Integrase-deficient lentivirus packaging

• Viral titer determination (up to 10⁸–10⁹ TU/mL)

• Quality control testing

3.2 Custom Services

• Promoter optimization and selection (CMV, EF1α, CAG, etc.)

• Fluorescent labeling or selection marker integration

• Special pseudotype packaging (for enhanced specificity of transduction)

• Concentration and purification services

3.3 Technical Support

• Experimental protocol design consultation

• Transduction condition optimization guidance

• Data analysis and interpretation support

• Post-service technical Q&A

4. Case Studies

Case Study 1: CRISPR Gene Editing Optimization

Client Need: Reduce off-target effects caused by prolonged Cas9 expression

Solution:

• Transient expression of Cas9-sgRNA via integration-deficient lentiviral vector

• Peak editing efficiency achieved at 72 hours post-transduction

• Cas9 expression undetectable after 1 week

Outcome: Editing efficiency of 65% achieved; off-target rate reduced by 80%

Case Study 2: iPSC Reprogramming (Integration-Free)

Client Need: Generate induced pluripotent stem cells without genomic integration

Solution:

• Co-transduction of four reprogramming factors (OSKM) via integration-deficient lentiviral vectors

• iPSC colonies appeared 2–3 weeks post-transduction

• Exogenous genes naturally eliminated upon passaging

• Absence of integration events confirmed by genomic PCR

Outcome: Successfully generated iPSCs free of exogenous gene residues, meeting clinical application standards

References

[1] Travieso T, Abdelaal HM, Dowd KA, et al. Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. npj Vaccines. 2020;5:34. doi:10.1038/s41541-020-0186-5

[2] Integrase defective lentiviral vector promoter impacts transgene expression in target cells and magnitude of vector-induced immune responses. Viruses. 2023;15(11):2255. doi:10.3390/v15112255

[3] Franceschini L, Margot M, Caputo A, et al. Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. npj Vaccines. 2022;7:49. doi:10.1038/s41541-022-00465-1

[4] Nidhi F, Tomatsu S. Integrase-deficient lentiviral vector as a platform for efficient CRISPR/Cas9-mediated gene editing for mucopolysaccharidosis IVA. Int J Mol Sci. 2025;26(14):6616. doi:10.3390/ijms26146616